Health & Fitness
Tue, May 8, 2012Mon, May 7, 2012Sat, May 5, 2012Fri, May 4, 2012Thu, May 3, 2012Wed, May 2, 2012Tue, May 1, 2012Mon, April 30, 2012Sun, April 29, 2012Sat, April 28, 2012Fri, April 27, 2012Thu, April 26, 2012Wed, April 25, 2012Tue, April 24, 2012Halozyme to Host First Quarter 2012 Financial Results Conference Call
Published in Health and Fitness on Monday, April 30th 2012 at 13:30 GMT by Market Wire
Halozyme to Host First Quarter 2012 Financial Results Conference Call -- SAN DIEGO, April 30, 2012 /PRNewswire/ --
Halozyme to Host First Quarter 2012 Financial Results Conference Call
SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: [ HALO ]) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.
(Logo: [ http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ])
The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to [ www.halozyme.com ] approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at [ www.halozyme.com ].
Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
[ aerickson@halozyme.com ]
SOURCE Halozyme Therapeutics, Inc.
[ Back to top ] RELATED LINKS
[ http://www.halozyme.com ]
